Per Johanson

Per Johanson

Auto-generated profile, based on publicly available information

Per Johanson

AstraZeneca Mölndal Sweden

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2019 in Circulation
Verified
Journal Article
Closed access
PDF file
EKEri T. Kato
Eri T. Kato
MSMichael G. Silverman
Michael G. Silverman
OMOfri Mosenzon
Ofri Mosenzon
TZThomas A. Zelniker
Thomas A. Zelniker
ACAvivit Cahn
Avivit Cahn
SWStephen D. Wiviott
Stephen D. Wiviott
Background: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) on the clinical benefit of sodium-glucose cotransporter 2 inhibition is unknown. Methods: In the DECLARE-TIMI 58 trial, baseline heart failure (HF) status was collected from all patients, and EF was collected when available. HF with reduced EF (HFrEF) was defined as EF <45%. Outcomes of interest were the composite of cardiovascular death/HHF, its components, and all-cause mortality. Results: Of 17 160 patients, 671 (3.9%) had HFrEF, 1316 (7.7%) had HF without known reduced EF, and 15 173 (88.4%) had no history of HF at baseline. Dapagliflozin reduced cardiovascular death/HHF more in patients with HFrEF (hazard ratio [HR], 0.62 [95% CI, 0.45–0.86]) than in those without HFrEF (HR, 0.88 [95% CI, 0.76–1.02]; P for interaction=0.046), in whom the treatment effect of dapagliflozin was similar in those with HF without known reduced EF (HR, 0.88 [95% CI, 0.66–1.17]) and those without HF (HR, 0.88 [95% CI, 0.74–1.03]). Whereas dapagliflozin reduced HHF both in those with (HR, 0.64 [95% CI, 0.43–0.95]) and in those without HFrEF (HR, 0.76 [95% CI, 0.62–0.92]), it reduced cardiovascular death only in patients with HFrEF (HR, 0.55 [95% CI, 0.34–0.90]) but not in those without HFrEF (HR, 1.08 [95% CI, 0.89–1.31]; P for interaction=0.012). Likewise, dapagliflozin reduced all-cause mortality in patients with HFrEF (HR, 0.59 [95% CI, 0.40–0.88;) but not in those without HFrEF (HR, 0.97 [95% CI, 0.86–1.10]; P for interaction=0.016). Conclusions: In the first sodium-glucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF, we found that dapagliflozin reduced HHF in patients with and without HFrEF and reduced cardiovascular death and all-cause mortality in patients with HFrEF. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01730534.

14 April 2020 in JAMA
Verified
Journal Article
Open access
PDF file
MPMark C. Petrie
Mark C. Petrie
SVSubodh Verma
Subodh Verma
KDKieran F. Docherty
Kieran F. Docherty
SISilvio E. Inzucchi
Silvio E. Inzucchi
IAInder Anand
Inder Anand
JMJohn J. V. McMurray
John J. V. McMurray
Inhibitors of the sodium-glucose cotransporter 2 (SGLT2), initially developed as a treatment for individuals with type 2 diabetes, prevent reabsorption of filtered glucose and lower blood glucose levels by increasing urinary excretion.1-3 In trials of participants with type 2 diabetes, these drugs led to a reduction in incident heart failure, which occurred early after randomization and appeared to be independent of baseline and time-dependent changes in glycated hemoglobin, suggesting this benefit may not necessarily be due to glucose lowering and might also be found in individuals without diabetes.4-8 In parallel, experimental evidence emerged suggesting that SGLT2 inhibitors may have cardioprotective actions independent of blood glucose level.9-11 The Dapagliflozin And Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial included patients with heart failure and reduced ejection fraction with and without type 2 diabetes. Dapagliflozin reduced the risk of worsening heart failure events and cardiovascular death and improved symptoms.12,13 The key question arising from the DAPA-HF trial is how the effects of dapagliflozin compared in patients with and without diabetes, and whether the findings of this trial support the hypothesis that SGLT2 inhibition might be an effective treatment for patients with heart failure, including those without diabetes. In this exploratory analysis, the efficacy of dapagliflozin, along with metabolic and hemodynamic changes and adverse events, were analyzed in patients with heart failure with reduced ejection fraction with and without diabetes and across the range of baseline glycated hemoglobin levels in DAPA-HF.

27 April 2011 in JAMA
Verified
Journal Article
Open access
PDF file
TJTomas Jernberg
Tomas Jernberg
PJPer Johanson
Per Johanson
CHClaes Held
Claes Held
BSBodil Svennblad
Bodil Svennblad
JLJohan Lindbäck
Johan Lindbäck
FSFor Swedeheart/Riks-Hia.
For Swedeheart/Riks-Hia.
Although recent population-based studies indicate a reduction in incidence, ST-elevation myocardial infarction (STEMI) is still a major health issue worldwide.1 In a recent study describing the current situation in 30 European countries, the annual incidence for hospital admissions for STEMI varied between 44 and 142 cases per 100 000 inhabitants, which is in keeping with recent data from North America.2,3

1 March 2012 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
OHOla Hammarsten
Ola Hammarsten
MFMichael L X Fu
Michael L X Fu
RSRuna Sigurjonsdottir
Runa Sigurjonsdottir
MPMax Petzold
Max Petzold
LSLina Said
Lina Said
PJPer Johanson
Per Johanson
BACKGROUND: High-sensitivity cardiac troponin T (cTnT) assays detect small clinically important myocardial infarctions (MI) but also yield higher rates of false-positive results owing to increased concentrations sometimes present in patients without MI. Better understanding is needed of factors influencing the 99th percentile of cTnT concentrations across populations and the frequency of changes in cTnT concentrations >20% often used in combination with increased cTnT concentrations for diagnosis of MI. METHODS: cTnT percentiles were determined by use of the Elecsys® hscTnT immunoassay (Modular® Analytics E170) in a random population sample, in emergency room (ER) patients, and in patients with non–ST-elevation MI (NSTEMI). Changes in cTnT concentrations were determined in hospitalized patients without MI. RESULTS: The 99th cTnT percentile in a random population sample (median age, 65 years) was 24 ng/L. In ER patients 65 years old it was 82 ng/L and highly age dependent. In hospitalized patients without MI the 97.5th percentile for change in the cTnT concentration was 51%–67%. cTnT remained below the 99th percentile (12 ng/L) in 1% of patients with NSTEMI until 8.5 h after symptom onset and 6 h after ER arrival. CONCLUSIONS: Age >65 years was the dominant factor associated with increased cTnT in ER patients. This age association was more prominent in ER patients than in a random population sample. Changes in serial cTnT concentrations >20% were common in hospitalized patients without MI.

5 November 2019 in Circulation
Verified
Journal Article
Closed access
PDF file
DBDavid D. Berg
David D. Berg
SWStephen D. Wiviott
Stephen D. Wiviott
BSBenjamin M. Scirica
Benjamin M. Scirica
YGYared Gurmu
Yared Gurmu
OMOfri Mosenzon
Ofri Mosenzon
MSMarc S. Sabatine
Marc S. Sabatine
Background: Patients with type 2 diabetes mellitus (T2DM) are at increased risk of developing heart failure. Sodium-glucose cotransporter-2 inhibitors reduce the risk of hospitalization for heart failure (HHF) in patients with T2DM. We aimed to develop and validate a practical clinical risk score for HHF in patients with T2DM and assess whether this score can identify high-risk patients with T2DM who have the greatest reduction in risk for HHF with a sodium-glucose cotransporter-2 inhibitor. Methods: We developed a clinical risk score for HHF in 8212 patients with T2DM in the placebo arm of SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53). Candidate variables were assessed using multivariable Cox regression, and independent clinical risk indicators achieving statistical significance of P 20-fold gradient of HHF risk ( P for trend <0.001) in both the derivation and validation cohorts, with C indices of 0.81 and 0.78, respectively. Although relative risk reductions with dapagliflozin were similar for patients across the risk scores (25%–34%), absolute risk reductions were greater in those at higher baseline risk (1-sided P for trend=0.04), with high-risk (2 points) and very-high-risk (≥3 points) patients having 1.5% and 2.7% absolute reductions in Kaplan-Meier estimates of HHF risk at 4 years, respectively. Conclusions: Risk stratification using a novel clinical risk score for HHF in patients with T2DM identifies patients at higher risk for HHF who derive greater absolute benefit from sodium-glucose cotransporter-2 inhibition. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifiers: NCT01107886 and NCT01730534.

1 October 2013 in JACC
Verified
Journal Article
Open access
CBChristian Bjurman
Christian Bjurman
MLMårten Larsson
Mårten Larsson
PJPer Johanson
Per Johanson
MPMax Petzold
Max Petzold
BLBertil Lindahl
Bertil Lindahl
OHOla Hammarsten
Ola Hammarsten
The purpose of this study was to examine the extent of change in troponin T levels in patients with non-ST-segment elevation myocardial infarction (NSTEMI). Changes in cardiac troponin T (cTnT) levels are required for the diagnosis of NSTEMI, according to the new universal definition of acute myocardial infarction. A relative change of 20% to 230% and an absolute change of 7 to 9 ng/l have been suggested as cutoff points. In a clinical setting, where a change in cTnT was not mandatory for the diagnosis of NSTEMI, serial samples of cTnT were measured with a high-sensitivity cTnT (hs-cTnT) assay, and 37 clinical parameters were evaluated in 1,178 patients with a final diagnosis of NSTEMI presenting <24 h after symptom onset. After 6 h of observation, the relative change in the hs-cTnT level remained <20% in 26% and the absolute change <9 ng/l in 12% of the NSTEMI patients. A relative hs-cTnT change <20% was linked to higher long-term mortality across quartiles (p = 0.002) and in multivariate analyses (hazard ratio: 1.61 [95% confidence interval: 1.17 to 2.21], p = 0.004), whereas 30-day mortality was similar across quartiles of relative hs-cTnT change. Because stable hs-TnT levels are common in patients with a clinical diagnosis of NSTEMI in our hospital, a small hs-cTnT change may not be useful to exclude NSTEMI, particularly as these patients show both short-term and long-term mortality at least as high as patients with large changes in hs-cTnT.